BMY

Bristol-Myers Squibb remains a scale biopharma with durable franchises in oncology, hematology and immunology, but its moat hinges on navigating major LOE pressure while replenishing its pipeline. Q1 2026 results showed the “growth portfolio” is still advancing, with management citing Camzyos, Breyanzi and Reblozyl as key drivers. Business development is an important lever, highlighted by the global BNT327 bispecific partnership with BioNTech, which expands BMY’s solid-tumor optionality but adds execution risk and near-term spend.

Financially, Q1 2026 revenue was $11.5B with non-GAAP EPS of $1.58, and the company reaffirmed 2026 guidance for revenue of about $46.0B–$47.5B and non-GAAP EPS of $6.05–$6.35 (trending toward the upper end). Balance-sheet leverage remains meaningful with roughly $44.5B total debt and about $9.6B cash at quarter-end, though BMY continues to fund a ~4.4% dividend. Valuation appears compressed (forward P/E cited near ~9x), suggesting the market is pricing in patent-cliff risk and skepticism around pipeline monetization.

Over the next 12 months, the stock likely trades on evidence that newer launches can outgrow erosion, plus incremental pipeline/partner updates (including BNT327 progress) and any reaffirmation/raise of 2026 guidance. Key risks are faster-than-expected declines in legacy brands, clinical/regulatory setbacks, and capital-allocation tradeoffs between debt reduction and sustaining the dividend.

Recommendation: HOLD. The yield and low multiple provide downside support, but the patent-cliff and pipeline execution uncertainty keep risk-reward balanced until growth products and late-stage assets more clearly re-rate earnings durability.